Advanced Search

 

Study ID Status Title Patient Level Data
207872 Recruiting A Proof of Principal Study to Investigate the Stain Control of Two Stannous Fluoride Dentifrices
207877 Recruiting Meta-Analysis to evaluate the impact of exacerbations on Health-Related Quality of Life, FEV1, risk of further exacerbations, and mortality using data from GSK COPD observational studies and those for Fluticasone Propionate, Salmeterol/Fluticasone Propionate, Fluticasone Furoate/Vilanterol, and mepolizumab
207878 Completed Efficacy and Safety of Belimumab in a Subgroup of Systemic Lupus Erythematosus (SLE) Patients with High Disease Activity (anti-dsDNA positive and low complement and SELENA-SLEDAI score >=10): A Pooled Analysis of the HGS1006-C1056 (BLISS-76) and HGS1006-C1057 (BLISS-52) Studies
207891 Not yet recruiting PGx7682 Exploratory Genetic Analysis for GSK2894512 for efficacy in atopic dermatitis patients in 203121
207926 Not yet recruiting PGx7680 Exploratory Meta-analysis of METRO (metformin response) and MetGen (Metformin response consortium)
207927 Not yet recruiting PGx7683_Exploratory PGx analysis for GSK1325760 (Ambrisentan) in 112565
207933 Active, not recruiting PGx7684: Confirmatory pharmacogenetic study investigating IL13 association with efficacy response to fluticasone furoate/vilanterol in asthma study 201378
207935 Not yet recruiting PGx7685:Exploratory PGx evaluation of adverse events observed in subjects treated with GSK3342830 in 204847 Part 2
207941 Not yet recruiting Meta-Analysis Plan for MID207941: A Study to Evaluate Risk Factors for Pneumonia and Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in a COPD Population of Patients Treated with GW685698 + GW642444 (Fluticasone Furoate + Vilanterol); GW642444 (Vilanterol); CCI18781 (Fluticasone Propionate); GR33343 (Salmeterol); CCI18781+ GR33343 (Fluticasone Propionate + Salmeterol) and Placebo
208091 Not yet recruiting Meta-analysis of studies MEA115588 and 200862 of mepolizumab (SB240563) to evaluate changes in AM PEF in severe eosinophilic asthma (eTrack Study Identifier 208091)
208099 Not yet recruiting PGx7687: Exploratory Pharmacogenetic Study to Investigate Efficacy of SB252263 Tafenoquine on relapse of P Vivax Malaria in TAF112582 and TAF115654
208108/091 Completed A phase II, double-blind, randomized study to compare the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB/Hib2.5 to GSK Biologicals’ Tritanrix™-HepB/Hiberix™ when administered as a three-dose primary vaccination course to healthy infants at 6, 10 and 14 weeks of age. A dose of unconjugated Hib vaccine (plain PRP booster) will be administered at the age of 10 months to 50% of the subjects Study Listed on ClinicalStudyDataRequest.com
208109/220 Completed A Phase IIIb, open, randomized, controlled, multicenter study of the immunogenicity and safety of GSK Biologicals' inactivated hepatitis A vaccine administered on a 0-6 mth schedule concomitantly with Wyeth Lederle's pneumococcal conjugate vaccine in healthy children 15 months of age Study Listed on ClinicalStudyDataRequest.com
208109/231 Completed Immunogenicity & Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With Merck & Company, Inc. Measles-Mumps-Rubella Vaccine (M-M-RII) & Merck & Co Varicella Vaccine (VARIVAX™) to Children 15 Months of Age Study Listed on ClinicalStudyDataRequest.com
208109/232 Completed Immunogenicity and Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) co-administered With GSK Biologicals' DTaP Vaccine (Infanrix™) and Aventis Pasteur's Haemophilus b Conjugate Vaccine (ActHIB) in Healthy Children 15 months of Age Study Listed on ClinicalStudyDataRequest.com
208115 Not yet recruiting Meta-analysis to further assess the efficacy of mepolizumab 100mg SC on selected endpoints and to further investigate the relationship between efficacy endpoints, blood eosinophils and other important subgroups
208116 Not yet recruiting Meta-analysis to further assess the efficacy of mepolizumab 100mg subcutaneous dose on selected endpoints in subjects eligible for omalizumab treatment and other related subgroups
208125 Not yet recruiting A meta-Analysis to compare the efficacy and safety of umeclidinium/vilanterol 62.5/25mcg versus Placebo, umeclidinium/vilanterol 62.5/25mcg versus tiotropium 18mcg and umeclidinium/vilanterol 62.5/25mcg versus fluticasone propionate/salmeterol 250/50 in subjects with Chronic Obstructive Pulmonary Disease (COPD) in the elderly
208127/132 (EXT Y2) Completed Evaluate the Persistence of Immune Response of GSK Biologicals' Twinrix™ Vaccine, Administered According to a 0,6 month Schedule and a 0,1,6 month Schedule, in Healthy Children Aged Between 1-11 years at the Time of First Vaccine Dose Study Listed on ClinicalStudyDataRequest.com
208129/002 Completed Study to evaluate the immunogenicity, reactogenicity and safety of GSK Biologicals' (previously SmithKline Beecham Biologicals') MPL-adjuvanted recombinant hepatitis B vaccine versus Engerix™-B, in haemodialysis patients
208129/004 Completed Study to evaluate the immunogenicity and reactogenicity of GSK Biologicals' MPL-adjuvanted recombinant hepatitis B vaccine in comparison with those of Engerix™-B in healthy adult volunteers following 2 different schedules
208129/005 Completed Study to evaluate the immunogenicity and reactogenicity of various formulations of GSK Biologicals’ (previously SmithKline Beecham Biologicals') recombinant hepatitis B vaccine with different adjuvants in healthy adult volunteers
208129/006 Completed Study to evaluate the immunogenicity and reactogenicity of various formulations of GSK Biologicals' (previously SmithKline Beecham Biologicals') recombinant hepatitis B vaccine in healthy adult volunteers
208129/009 Completed Study to compare the immunogenicity, safety and reactogenicity of GSK Biologicals’ (previously SmithKline Beecham Biologicals') recombinant hepatitis B vaccines with and without adjuvant in healthy older adult volunteers
208129/016 Completed Study to compare the safety, immunogenicity and reactogenicity of different formulations of GSK Biologicals' (previously SmithKline Beecham Biologicals') MPL-adjuvanted recombinant hepatitis B vaccine to that of Engerix™-B

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.